The treatment targets for pulmonary arterial hypertension (PAH) continue to evolve. Recent advances have expanded therapeutic targets beyond the conventional endothelin, nitric oxide, and prostacyclin pathways to include the activin-bone morphogenetic protein receptor type II BMPR-II signaling axis. These novel disease-modifying approaches aim to improve exercise capacity and reduce the risk of clinical worsening. Test your knowledge with this quick question on contemporary PAH management!
(Scroll down to answer the question) ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no explicit or implied warranties about the information's suitability, reliability, or adequacy, including data visualization elements and graphics. We do not endorse any medical treatment, product, ideas, or service, including…
